Evaluation of blood units with isolated anti HBC for the presence of HBV DNA

Abdel-Rahman N. Zekri^a, Azza A. Awlia^b, Hadeer El Mahalawi^a, Emad F. Ismail^c and Gamal M. Mabrouk^{b,*}

^a*Virology and immunology Unit Cancer biology Department and Clinical Pathology Department National Cancer Institute, Cairo, Egypt*

^b*Virology and Immunology Laboratory, King Fahd General Hospital, Jeddah, Saudia Arabia*

^c*Oncology Diagnostic Unit, Suez Canal University, Egypt*

Abstract. We screened blood donors in one center in Saudi Arabia for a safety transfusion. We found that among 5043 blood donors negative for HCV and HIV, the incidence of HBsAg positivity was 2.97%. When antiHBc antibody was measured (HBcIg) in HBsAg negative donors, we observed that 21.47% were positive indicating previous exposure to hepatitis B virus. The HBcIg positive blood was further screened for HBsAb and the specimens were found to be reactive in 81.54%. Based on these data blood transfusion was permissible from donors who showed HBsAg negativity, HBcIg positive and HBsAb reactive blood. In order to ensure safety transfusion an aliquot of specimens ($n = 80$) was further analyzed for HBV DNA by PCR. We found only one specimen positive with incidence of 1.25%. So we recommended restricting transfusion from the previously mentioned donors to emergencies.

Keywords: Blood units, HBsAg, HBcIg, HBV DNA, Saudi

1. Introduction

Hepatitis B viral infection is a major cause of acute and chronic hepatitis, cirrhosis and hepatocellular carcinoma, and is one of the 10 most common causes of death worldwide [15]. Most of the acutely infected adults recover spontaneously and completely from acute HBV infection. Only a small fraction (3–5%) of HBV infected adults become chronic carriers of hepatitis B surface antigen, which is a marker for chronic infection. Children born to infected mothers or infected in the first year of life are more susceptible to chronic infection [20]. The number of HBV carriers was also reported to be more than 350 million worldwide [14]. This carrier rate was shown to be higher

when there is associating risk factor as schistosomiasis [9].

In Saudi Arabia there were many sporadic studies in different locations with no statistical records but the prevalence rate of HBsAg in high risk groups, such as intravenous drug users, was shown to be 6.1% compared to 0.5% in non intravenous drug users [19]. Another risk factor in blood donations is GB virus C (hepatitis G), which was reported to be prevalent in 2% of healthy Saudi donors as estimated by RT-PCR [1]. A third risk factor is hepatitis C of which the prevalence rate in healthy Saudi donors was estimated from our records to be 0.7% (unpublished data).

HIV, HTLV and sexually transmitted diseases are not considered a major problem in Saudi donors. The risk of transmission is very low and there are no records or reported studies of HIV or HTLV transmitted virus through transfusion.

The above mentioned records demonstrate that HBV infection is a major health problem that deserves more attention, especially in the field of blood transfusion,

* Address for correspondence: Gamal M. Mabrouk MD, PhD, Oncology Diagnostic Unit, Ain Shams Faculty of Medicine, Abbassia, Cairo, Egypt. Tel.: +202 6859928; E-mail: gamaL.mabrouk@hotmail.com.

as little or no reports to our knowledge are available regarding prevalence in healthy donors or in post transfusion hepatitis.

The incidence of post-transfusion hepatitis B has been greatly reduced by screening blood donors for HBsAg. However, HBV still accounts for a certain number of post-transfusion hepatitis. Residual risk of post-transfusion HBV infection due to seroconverting donors has been estimated to be 1 per 63,000 units [23]. It was found that the addition of anti-HBc screening helped in preventing some cases of HBV transmission [24].

With the advantage of genomic amplification methods, the potential use of HBV DNA detection was raised but has not yet been implemented in any country for blood screening [3]. It was anticipated that the extreme sensitivity of this technology would potentially be effective in identifying donations capable of transmitting HBV in the absence of detectable HBsAg, either early in infection or following clearance of HBsAg when anti-HBc is present in the absence of high titre of Anti-HBs [2].

Therefore, we attempted to study the potential HBV infectivity of anti-HBc +ve blood donation by the use of genomic amplification of viral DNA, in order to assess the safety of HBsAg -ve/Anti-HBc +ve blood unit for blood donation.

2. Donors and materials

All blood donations were carried out over a period of seven months (October 1999–April 2000). Blood donors were questioned and proved to be apparently healthy by excluding those who had histories of previous operations, tattooing, blood transfusion or drug addiction as potential sources of infections.

HBsAg was measured by Abbott Auszyme monoclonal qualitative third generation enzyme immunoassay kit. Hepatitis BcIg total and HBsAb were determined by Abbott enzyme immunoassay kit. HBV DNA was carried out by qualitative in-house PCR using primers from pre-s regions as described previously [6]. This amplified a highly conserved region of 460 bp that has been shown to increase the precision of detection and quantification of HBV DNA as described previously [8]. All blood specimens were also checked routinely for HCV Ab, HIV Ab, HIV P24, HTLV and RPR.

Table 1

HBcIg positivity in HBsAg positive and negative sera of blood donors

	HBcIg +ve	HBcIg% positivity
HBsAg +ve <i>n</i> = 150	<i>n</i> = 150	100%
HBsAg -ve <i>n</i> = 4893	<i>n</i> = 1051	21.47%

Total number of donors = 5043 HBsAg +ve 2.97%.

Table 2

HBsAb positivity in HBcIg positive, HBsAg negative donors

	HBsAb (<i>n</i>)	HBsAb% positivity
HBcIg +ve <i>n</i> = 1051	<i>n</i> = 857	81.54%

Table 3

HBV DNA in HBcIg positive and negative sera

	HBcIg +ve <i>n</i> = 80	HBcIg -ve <i>n</i> = 22 (control)
HBV DNA	one (1.25%)	none (zero%)

3. Results

Screening the HBsAg positive blood showed almost 100% positivity for HBc Ig, whereas HBsAg negative sera showed only 21% positivity, indicating previous exposure to the virus (Table 1). These results demonstrate the prevalence rate of carrier state of HBV to be 2.97%.

Table 2 demonstrates that more than 4/5 of the blood donors developed immunity against viral exposure after disappearance of HBsAg and developing anti HBc.

The polymerase chain reaction results for HBV DNA were negative in all random samples except one (Table 3). The positive specimen was HBsAg negative and anti-HBc positive. When the anti HBc negative sera were analyzed for HBV DNA as a control, all specimens (*n* = 22) were negative.

4. Discussion

Screening of blood donors for HBsAg has greatly reduced the risk of post-transfusion HBV infection. Residual risk for post transfusion (PT) HBV infection due to seroconverting donors, or due to the existence of individuals with immuno-silent HBV infections who have detectable HBV DNA sequences in serum and/or liver still remains as a possibility [3].

The inclusion of anti-HBc as a method of screening of blood donors is not yet settled. Some considered that the use of this additional marker of HBV infection remained useful on two accounts: to eliminate infectious blood units carrying anti-HBc as the

only serologic marker of HBV infection [23], and to serve as an indicator of life style for high risk populations who may carry known or unknown transmissible viruses [4]. However, it has been shown that PT HBV infections originating from blood donors without any HBsAg markers are relatively frequent [18,21]. Such a situation can be related either to donations collected during the serologically silent window-period or to a variant of HBV that induces an antibody response not detected by anti-HBc assays [10], or to exceptional individuals who do not respond to HBV antigens. In none of these situations will anti-HBc screening be efficient in the prevention of transfusion transmission of HBV. HBV DNA screening in individual donations should be able to prevent most window period-related infections and infection by variants, provided that the amplification primers are chosen in a sufficiently conserved region of the genome [2].

It was previously shown that the frequency of HBV DNA in samples with isolated anti-HBc from low risk groups such as blood donors were either negative [17, 25] or with a percentage of positivity ranging between 7% and 30% [11,18].

In our study, HBV DNA was detected in 1.2% of the samples tested for HBV DNA from HBsAg negative/anti HBc positive blood donors. Our results are in agreement with another study which showed that HBV DNA was positive in 3.5% of HBsAg negative blood samples of apparently healthy individuals [5]. Similarly, some recent studies revealed that HBV wasn't cleared even after the disappearance of HBsAg and that HBV DNA could be detected in a substantial proportion of healthy donors who are anti-HBc positive [16, 28].

HBV apparent clearance as demonstrated by the positive HBV DNA in HBsAg negative specimens may be attributed to the presence of HBsAg mutant forms that were undetected by the available screening assays [13]. The clearance also may be due to the existence of hepatocytes containing non-secreting viral surface proteins (due to S promotor mutants) within the dilated vesicles encountered in chronic hepatitis B [27].

In China a high incidence of HBV DNA was found among blood donors though they were screened for HBsAg [26]. Furthermore, HBV DNA was detected in HBsAg negative/anti-HBc positive blood showing statistical significant relationship between HBV DNA and titer of anti-HBc as HBV DNA was only detected in blood with high titers of anti-HBc [22]. Other studies also showed that in HBsAg negative population the latter becomes immunocomplexed and escapes detection

by standard tests. Such population was shown to be positive for HBV DNA by PCR [12]. It was therefore recommended to exclude from transfusion blood from those donors [28].

On the other hand, HBV DNA was not detected at all in anti-HBc positive blood donors in Northwestern Greece [29]. In the study of Zervou and his colleagues, anti-HBc reactivity was found in 282 donors from a total of 6696 donors (4.2%); none tested HBV DNA positive. In addition they denied the occurrence of any case of transfusion associated HBV infection after the transfusion of isolated anti-HBc positive units [29]. In another study no donations with isolated anti-HBc were HBV DNA confirmed positive [2].

Thus, it is clear that the data available about HBV DNA screening of isolated anti-HBc positive samples is still controversial. It remains that each area determines the risk of PT hepatitis following the transfusion of seronegative blood according to its own results. As zero risk remains a strong objective in blood transfusion, the use of Nucleic Acid Testing (NAT) for screening blood units is of potential value. We recommend NAT screening of anti-HBc positive blood in our region as the presence of HBV DNA has been detected in 1.2% of isolated anti-HBc blood donors. NAT is expected to reduce the pre-antibody seroconversion window period as it was reported for HCV and HIV infected donations [7].

Acknowledgement

We would like to thank Mr. Yosof Basalama in the blood bank of KFGH for his cooperation during this work. This work was supported financially by Ministry of Health of Saudi Arabia, National Cancer Institute Cairo, and Oncology Diagnostic Unit, Suez Canal University, Egypt.

References

- [1] M.N. Al-Ahdal, M.A. Rezeig, G. Kessie, F. Chaudhry and F.U. Al Shammery, GB virus C/hepatitis G virus infection in Saudi Arabian blood donors and patients with cryptogenic hepatitis, *Arch Virol.* **145**(1) (2000), 73–84.
- [2] J.P. Allain, P.E. Hewitt, R.S. Tedder and L.M. Williamson, Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion, *Brit J Haematol.* **107** (1999), 186–195.
- [3] B. Ballieres, Will genome detection replace serology in blood screening for microbial agents? *Pract Res Clin Haematol.* **13**(4) (2000), 615–629.

- [4] M.A. Blajchman, S.B. Bull and S.V. Feinman, Post-transfusion hepatitis: impact of non A, non B, Surrogate tests. Canadian post-transfusion hepatitis prevention study group, *Lancet* **345** (1995), 21–25.
- [5] P. Bodhiphala, S. Chaturachumroenchai, P. Chiewslip and P. Pruksananonda, Detection of HBV genome by gene amplification method in HBsAg negative blood donors, *J Med Assoc Thai*. **82**(5) (1999), 491–495.
- [6] R. Boom, J. Solc, R. Heijntink, P.M. Wertheim-Van Dillen and J. van der Noorda, Rapid purification of hepatitis B virus DNA from serum, *J Clin Microbiol*. **29**(9) (1991), 1804–1811.
- [7] M.E. Chamberland, H.J. Alter, M.P. Busch, G. Nemo and M. Ricketts, Emerging infectious disease issues in blood safety, *Emerging Infectious Diseases* **7**(3) (2001), 552–553.
- [8] P. Coursaget, Y. Buisson, C. Bourdil, B. Yvonnet, C. Molinie, M.T. Diop, J.P. Chiron, O. Bao and I. Diop-Mar, Antibody response to preS1 in hepatitis B virus-induced liver disease and after immunization, *Res Virol*. **141** (1990), 563–570.
- [9] Y.A. Ghaffar, S.A. Fattah, M. Kamel, R.M. Badr, F.F. Mahomed and G.T. Strickland, The impact of endemic schistosomiasis on acute viral hepatitis, *Am J Trop Med Hyg*. **45**(6) (1991), 743–750.
- [10] K. Gottoh, S. Mima, T. Uchida, T. Shikata, K. Yoshizawa, M. Irie and M. Mizui, Nucleotide sequence of hepatitis B virus isolated from subject without serum anti-hepatitis B core antibody, *J Med Virol*. **46** (1995), 352–354.
- [11] H. Iizuka, K. Ohmura, A. Ishijima, K. Satoh, T. Tanaka, F. Tsuda, H. Okamoto, Y. Miyakaway and M. Mayumi, Correlation between anti-HBc titres and HBV DNA in blood units without detectable HBsAg, *Vox Sanguinis*. **63** (1992), 107–111.
- [12] H.I. Joller-Jemelka, A.N. Wicki and P.J. Grobe, Detection of HBs antigen in “anti-HBc alone” positive sera, *J Hepatol*. **21**(2) (1994), 269–272.
- [13] J.M. Jongerius, M. Wester, H.T. Cuypers, W.R. van-Oostendorp, P.N. Lelie, C.L. van-der-Poel and E.F. van-Leeuwen, New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays, *Transfusion* **38**(1) (1998), 56–59.
- [14] G.M. Lauer and B.D. Walker, Hepatitis C virus infection, *N Engl J Med*. **345**(1) (2001), 41–52.
- [15] W.M. Lee, Hepatitis B virus infection, *N Engl J Med*. **337** (1997), 1733–1745.
- [16] H. Marusawa, S. Uemoto, M. Hijikata, Y. Ueda, K. Tanaka, K. Shimotohne and T. Chiba, Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen, *Hepatology* **31**(2) (2000), 488–495.
- [17] M.H. Molijn, J.M. Vander Linden, K. Kol, J. Gorgles, W. Hop and D.J. van Rhenen, Risk factors and anti-HBc reactivity among first time blood donors, *Vox Sanguinis* **72** (1997), 207–210.
- [18] T.W. Mosley, C.E. Stevens, R.D. Aach, F.B. Hollinger, L.T. Mimms, L.R. Soloman, L.H. Barbosa and G.I. Nemo, Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients, *Transfusion* **35** (1995), 5–12.
- [19] J. Njoh and S. Zimmo, Prevalence of antibody to hepatitis D virus among HBsAg-positive drug dependent patients in Jeddah, Saudi Arabia, *East Afr Med J*. **75**(6) (1998), 327–328.
- [20] M. Peters, M.E. Vierling, D. Milich, F.V. Chisari and J.H. Hoofnagle, Immunology and the liver, *Hepatology* **13** (1991), 977–994.
- [21] J.W. Rasenach, H.J. Schlayer, F. Hettler, T. Peters, A.S. Preisler and W. Gerok, Hepatitis B virus infection without immunological markers after open-heart surgery, *Lancet* **345** (1995), 355–357.
- [22] F. Ren, H. Li and H. Zhao, Studies on hepatitis B virus infection in blood donors with positive anti-HBc and negative HBsAg, *Zhonghua Yu Fang Yi Xue Za Zhi* **32**(1) (1998), 7–9, (abstract).
- [23] G. Tegtmeyer, S. Henderson, A. McNamara and M. Kuhns, (a): Contribution of anti-HBc screening to blood safety at a regional blood center in the United States, *Transfusion* **37** (1997), S439.
- [24] G. Tegtmeyer, S. Henderson, P. Parton, K. Vance, R. Edwards, A. McNamara and M. Kuhns, (b): Acute hepatitis B infection after blood transfusion is not due to occult hepatitis B infection in donors, *Transfusion* **37** (1997), S440.
- [25] D.P.J. Turner, M. Zuckerman, G.J.M. Alexander, J. Waite and T. Wreighitt, Risk of inappropriate exclusion of organ donors by introduction of hepatitis B core antibody testing, *Transplantation* **63** (1997), 775–777.
- [26] M.C. Wang, D.M. Tan and X.J. Cao, A prospective study of post-transfusion hepatitis B virus infection, *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* **14**(1) (2000), 77–79, (abstract).
- [27] Xu-Z and Yen-TS, Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles, *J virol*. **70**(1) (1996), 133–140.
- [28] H. Yotsuyanagi, K. Yasuda, K. Moriya, Y. Shintani, H. Fujie, T. Tsutsumi, N. Nojiri, T. Juji, H. Hoshino, K. Shimoda, K. Hino, S. Kimura, S. Iimo and K. Koike, Frequent presence of HBV in the sera of HBsAg negative, anti-HBc positive blood donors, *Transfusion* **41**(9) (2001), 1093–1099.
- [29] E.K. Zervou, G.N. Dalekos, D.S. Boumba and E.V. Tsianos, Value of anti-HBc screening of Blood donors for prevention of HBV infection: results of a 3-year prospective study in Northwestern Greece, *Transfusion* **41**(5) (2001), 625–628.